Accelerating the pace of drug discovery

Paraza Pharma, Inc. is an innovative company with an aim to significantly improve the efficiency of the drug discovery process. Our experienced drug discovery team will help you design, define, execute, and meet your program milestones from lead identification through lead optimization and development candidate selection.

Learn more
“You have assembled a truly remarkable team who not only knows how to present science but also knows the science of drug discovery in depth”
Client Testimonial

Management

Arshad Siddiqui, Ph.D.
President & CEO

Dr. Siddiqui founded Paraza Pharma in 2011 after twenty-two years of a successful career in the biotechnology and pharmaceutical industries in Canada and USA. Dr. Siddiqui has held senior level positions in companies such as Shire-BioChem Pharma (Montreal, Canada), Neogenesis Pharmaceuticals (Cambridge, MA), Schering-Plough Corporation (Cambridge, MA) and Merck & Co. (Cambridge, MA).

Dr. Siddiqui completed a Ph.D. degree in Organic Chemistry at the University of Waterloo (Canada). As a drug discovery scientist and an entrepreneur, Dr. Siddiqui has been a co-recipient of the Prix-Galien (Canada, 1996) for the co-discovery of Epivir, Prix Genesis (Canada, 2013) and University of Waterloo Distinguished Alumni Award (2015). Dr. Siddiqui is an inventor on eighty-one patents and co-authored seventy-six research papers.

Jean-Marc Lachance, CA, CPA, MBA
Vice-President, Finance & Administration

Mr. Lachance joined Paraza Pharma as Executive Director of Finance and Administration in 2016. Mr. Lachance is a member of the Chartered Professional Accountants and has a MBA (Finance) from Hautes Études Commerciales, Université de Montréal.

Mr. Lachance has over twenty years of experience as a senior member of the executive team in the healthcare, biotechnology and banking industries. His responsibilities included CFO and Head of Finance in both private and public companies.

Claudio Sturino, Ph.D.
Vice-President, Chemical Sciences

Dr. Sturino joined Paraza Pharma as Executive Director of Chemical Sciences in 2017. Prior to joining Paraza Pharma, Dr. Sturino held several senior level positions at global pharmaceutical companies such as Vertex Pharmaceuticals Canada, Boehringer Ingelheim, Canada and Merck Frosst Canada.

Dr. Sturino brings over twenty years of experience in medicinal chemistry and drug discovery where he worked in the therapeutic areas of inflammation, respiratory, infectious disease and ion channels. Dr. Sturino contributed to the discovery and development of several clinical candidates including key contributions to the discovery of Laropiprant, a PGD2 antagonist.

Dr. Sturino completed a Ph.D. degree in Organic Chemistry from the University of Ottawa, Canada and a Postdoctoral Fellowship at the Ohio State University, USA with Professor Leo Paquette. He is a reviewer for multiple peer reviewed journals and has received numerous awards and honors. Dr. Sturino has co-authored well over thirty publications and contributed to over twenty patents. Dr. Sturino is also an Adjunct Professor of Chemistry at Laval University (Canada).

Stéphane Ciblat, Ph.D.
Director, Chemical Sciences

Dr. Ciblat joined Paraza Pharma in 2012. Prior to joining Paraza Pharma, Dr. Ciblat worked at several biotechnology companies including Targanta Therapeutics and Bellus Health.

Dr. Ciblat has sixteen years of experience in the pharmaceutical industry and contributed to the discovery of multiple compounds in the areas of oncology, immune-oncology, immunology, CNS, metabolic diseases, and anti-infectives. Dr. Ciblat’s contributions also include the discovery and development of four clinical candidates.

Dr. Ciblat completed a Ph.D. degree in Organic Chemistry from Université Blaise Pascal (France) and a Postdoctoral Fellowship at the Ohio State University, USA with Professor Leo Paquette. Dr. Ciblat co-authored twelve publications and is a co-inventor on seventeen patents.

Alexandre Larivée, Ph.D.
Director, Chemical Sciences

Dr. Larivée joined Paraza Pharma in 2011. Prior to joining Paraza Pharma, Dr. Larivée worked at Merck Frosst Canada as Senior Research Scientist.

Dr. Larivée has eleven years of experience in the pharmaceutical industry and has successfully managed several drug discovery programs in the areas of oncology, inflammation, CNS and infectious diseases leading to identification of two clinical candidates. Additionally, Dr. Larivée has extensive experience in state-of-the-art chemistry including asymmetric synthesis, flow, photocatalysis and electrochemistry.

Dr. Larivée completed his Ph.D. degree in Organic Chemistry from Université de Montréal, Canada and a Postdoctoral Fellowship at the Max-Planck Institute für Kohlenforschung, Germany with Professor A. Fürstner. Dr. Larivée has co-authored nine publications and is a co-inventor on three patents.

Peter White, Ph.D.
Vice-President, Biological Sciences/DMPK

Dr. White joined Paraza Pharma in 2015 as Executive Director of Biological Sciences.  Prior to joining, Dr. White held senior level positions at pharmaceutical companies such as Novartis Institutes for Biomedical Research (Emoryville, CA) and Boehringer Ingelheim, Canada.

Dr. White has twenty-five years of experience in the pharmaceutical industry and contributed to the development of multiple programs in the fields of virology and oncology. He has extensive experience in the development of novel biochemical and cellular screening assays, as well as the determination of inhibitor mechanisms of action. He has been a key contributor to the development of the HCV protease inhibitor, Falaprevir.

Dr. White completed a Ph.D. in Organic Chemistry from Colombia University, USA  and a Postdoctoral Fellowship in Enzymology at the University of California at Berkeley, USA.  Dr. White has co-authored forty-one publications and is an inventor on six patents.

Édith Bellavance, M.Sc.
Associate Director, DMPK

Ms. Bellavance joined Paraza Pharma in 2013. Prior to joining Paraza Pharma, Ms. Bellavance worked at Boehringer Ingelheim, Canada and Charles River, Canada.

Ms. Bellavance has over fifteen years of experience in the area of DMPK where she has been responsible for developing and optimizing in vitro and in vivo models to study preclinical drug candidates.

Ms. Bellavance completed her B.Sc. in Biochemistry from Université de Sherbrooke, Canada and M.Sc. in Molecular Endocrinology and Oncology at Université de Laval, Canada. She has co-authored six publications.

Limei Tao, Ph.D.
Manager, Bioanalysis

Dr. Tao joined Paraza Pharma in 2015. Prior to joining Paraza Pharma, Dr. Tao held positions at the National Research Council of Canada, Charles River, Canada and Bellus Health.

Dr. Tao has over fifteen years of experience in the pharmaceutical industry with specialization in DMPK and mass spectrometry. Additionally, Dr. Tao has been a key contributor to projects involving proteomics.

Dr. Tao completed her Ph.D. in Organic Chemistry from Concordia University, Canada. She has co-authored ten publications.

Danièle DesChênes, LLB, MBA
Chief Legal Counsel

Ms. Danièle DesChênes is a business and intellectual property lawyer with more twenty-five years of experience as a legal counsel for companies in the life sciences industry. Ms. DesChênes has a law degree from the Université de Montréal, a MBA (Finance) from Hautes études Commerciales, Université de Montréal, a Certificate on European business law and issues dealing with market access.

Serge Lamothe, Ph.D.
Director, Project Management & External Alliances

Dr. Lamothe began his career as a Medicinal Chemist and has since held various senior level positions in research for various pharmaceutical companies including Shire-Biochem Pharma, Innodia and Bellus Health prior to joining Paraza Pharma in 2016. He obtained a Ph.D. in Organic Chemistry from Université de Sherbrooke, Canada followed by a postdoctoral training at McGill University, Canada. He is a co-author on twenty-eight publications and an inventor on ten patents. In addition to his scientific background, Dr. Lamothe also holds a BAA in Accounting Sciences from Université du Québec à Montréal, Canada.

Diane Sauvé
Manager, Office Operations

Ms. Sauvé joined Paraza Pharma in 2013. Prior to joining Paraza, she worked for the Montreal Children’s Hospital as Administrative Agent. She has extensive experience in administrative office management in the pharmaceutical industry as well as the hospital environment.  Amongst others, she worked for over twenty years in the Research Division of Merck Frosst Canada and at Hoffmann-LaRoche Limited.

Brigitte MacKay, CRHA
Director, Human Resources & Talent Management

Ms. MacKay has over twenty years of experience in the field of human resources. Prior to joining Paraza Pharma in 2019, she was Lead, Learning & Development, for Nestlé Skin Health (Canada). Over the years, Ms. MacKay has developed and implemented innovative HR solutions to drive business strategy for companies such as Bombardier Aerospace and Merck Frosst Canada. She has a B.Sc. from Université de Montréal in Economics and Human Resources and is a member of the Ordre des Conseillers en Ressources Humaines du Québec.

Scientific Advisory Board

W. Robert Bishop
Ph.D

Dr. Bishop received his Ph.D. in Biochemistry & Molecular Biology from the University of Connecticut Health Center, followed by five years of post-doctoral research at Duke University Medical Center. He has authored over 70 peer-reviewed publications and several comprehensive reviews, primarily in the area of signal transduction in cancer cells. He has over 25 years of experience in oncology drug discovery and early development from target validation through clinical proof of concept at Schering-Plough Research Institute and Merck Research Labs. He possesses an in-depth knowledge of signal transduction pathways in cancer cells and cancer pharmacology and has expertise in oncology drug discovery and early development.

William (Bill) J. Greenlee, Ph.D.

Dr. Greenlee received his Ph.D. degree from Harvard University with Professor Robert Woodward. Dr. Greenlee has worked at Merck Research Laboratories, Rahway, NJ, and at the Schering-Plough Research Institute, Kenilworth, NJ, Dr. Greenlee has been in senior leadership positions in these companies heading up large medicinal chemistry groups. His career spans over 35 years, and includes contributions to the discovery of enalapril (Vasotec™) and lisinopril (Prinivil™), as well as other drug candidates that are currently in clinical trials. Dr. Greenlee has been the recipient of numerous honors and awards including the Alfred Burger Award in Medicinal Chemistry from the American Chemical Society (ACS) in 2004. He was inducted into the ACS Medicinal Chemistry Hall of Fame in 2006 and was elected a Fellow of the ACS in 2009. Dr. Greenlee is also a Perspectives Editor for the Journal of Medicinal Chemistry, and serves on the Editorial Advisory Board for ACS Medicinal Chemistry Letters. Dr. Greenlee is co-author of over 200 research papers, and an inventor of over 70 issued U.S. patents.

Timothy F. Jamison, Ph.D.

Dr. Jamison, Full Professor in the Department of Chemistry of the Massachusetts Institute of Technology (MIT), received his Bachelor’s degree from the University of California, Berkeley, and Ph.D. from Harvard University. Professor Jamison has received numerous honors and awards in recognition of his research contributions, including the Royal Society of Chemistry Merck Award, American Chemical Society Cope Scholar Award, Sloan Research Fellowship, GlaxoSmithKline Scholar Award, Amgen Young Investigator Award, Boehringer Ingelheim New Investigator Award, National Science Foundation CAREER Award, 3M Innovation Award. Professor Jamison’s research program focuses on the development of new methods and continuous flow technologies for the synthesis of organic molecules. Professor Jamison has published over 100 research articles and 15 patents.

Peter Winocour, Ph.D.

Dr. Winocour has over 12 years in academia and 15 years of in-depth multidisciplinary experience in the pharmaceutical industry in areas of discovery and preclinical development of small molecule drugs, including pharmacokinetics, toxicology, efficacy models, project management and preparation and submission of IND/CTA/IMPD packages to regulatory authorities. He was Head of the Pharmacology and Toxicology Department at Shire-Biochem Pharma and Director of Preclinical Development at Aegera Therapeutics. Previously, Dr. Winocour was an Associate Professor in the Department of Pathology at McMaster University and an Adjunct Professor in the Department of Pathology at McGill University. Dr. Winocour holds a Ph.D. from the University of Southampton, UK, and has published over 76 research papers and has 34 invited lectures.

Partner with us!

Whether working as fully integrated members of your drug discovery team or providing expertise to solve specific problems, our world-class Drug Discovery Experts can help you reach your project goals.

Faces of Paraza

We're Currently Hiring!

Paraza Pharma, Inc. is a rapidly growing drug discovery research organization which offers a dynamic and collaborative work environment where scientific excellence, innovation and creativity are at the forefront.